Australian Regenerative Medicine Institute

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(3)

Patients who would like a brand of drug that costs more than the lowest price subsidized by the scheme are required to pay the difference between the lowest priced brand and the brand prescribed. A minimum pricing policy was introduced in December 1990 to allow pharmaceutical manufacturers to set their own price on items covered by the PBS made by several manufacturers . Bioequivalence of available brands of particular drugs is determined by the TGA during the process of registration, and generic substitution is allowed within the PBS if such products are flagged as bioequivalent in the schedule.

Professional fees paid to pharmacists for prescriptions ($4.06 for most and $5.89 for extemporaneous items) and their margins on a wholesaler’s price (currently 10% up to $180, $18 up to $360 and 5% above $360) are determined by an independent tribunal, the Pharmaceutical Benefits Remuneration Tribunal. The wholesaler’s margin on suppliers price is currently set at 10%. buy ortho tri-cyclen

The National Health Act provides other programs for reimbursement of drugs. For example, certain highly specialized and expensive drugs are made available for use through hospital out-patient departments under SECTION 100, eg, dor-nase alfa for certain patients with cystic fibrosis and clozapine for patients who are nonresponders or intolerant of other neuroleptics . Approval for listing drugs as available under Sec 100 is decided after review of applications by the Pharmaceutical Benefits Advisory Committee (PBAC), and the Commonwealth and state work out cost-sharing between in-patient and out-patient use.

Category: Pharmaceutical

Tags: Australian Pharmaceutical Benefits Scheme, Canadian health care, Pharmaceutical policy, Pharmacoeconomics

Leave a Reply

Your email address will not be published. Required fields are marked *